BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11965826)

  • 21. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes and dyslipidaemia.
    Schwartz SL
    Diabetes Obes Metab; 2006 Jul; 8(4):355-64. PubMed ID: 16776742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM; Barrow BA; Grant PJ; Levy JC
    Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid abnormalities in insulin resistant states.
    Watson KE; Horowitz BN; Matson G
    Rev Cardiovasc Med; 2003; 4(4):228-36. PubMed ID: 14668690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dyslipoproteinemia and diabetes mellitus].
    Vaverková H
    Vnitr Lek; 2000 Sep; 46(9):532-8. PubMed ID: 11344647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lipid-lowering therapy in patients with type-2 diabetes mellitus].
    Pados G; Audikovszky M
    Orv Hetil; 2003 Mar; 144(12):557-61. PubMed ID: 12723526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
    Koga H; Sugiyama S; Kugiyama K; Fukushima H; Watanabe K; Sakamoto T; Yoshimura M; Jinnouchi H; Ogawa H
    Eur Heart J; 2006 Apr; 27(7):817-23. PubMed ID: 16434416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials and lipid guidelines for type II diabetes.
    Prisant LM
    J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
    Pastromas S; Terzi AB; Tousoulis D; Koulouris S
    Int J Cardiol; 2008 May; 126(1):3-12. PubMed ID: 17689745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.
    Bruckert E; Baccara-Dinet M; Eschwege E
    Diabet Med; 2007 Apr; 24(4):388-91. PubMed ID: 17335463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.